AstraZeneca’s (AZN) Hold Rating Reaffirmed at Shore Capital

Share on StockTwits

Shore Capital reiterated their hold rating on shares of AstraZeneca (LON:AZN) in a research report sent to investors on Tuesday morning.

Several other analysts have also issued reports on AZN. JPMorgan Chase & Co. set a GBX 5,800 ($75.79) target price on AstraZeneca and gave the company a buy rating in a research note on Monday, July 9th. Barclays reiterated an overweight rating and issued a GBX 6,500 ($84.93) price target (up from GBX 6,300 ($82.32)) on shares of AstraZeneca in a research report on Tuesday, July 10th. Jefferies Financial Group lifted their price target on AstraZeneca from GBX 6,000 ($78.40) to GBX 6,050 ($79.05) and gave the company a buy rating in a research report on Friday, July 13th. Deutsche Bank reiterated a buy rating and issued a GBX 6,000 ($78.40) price target (up from GBX 5,700 ($74.48)) on shares of AstraZeneca in a research report on Friday, July 13th. Finally, Liberum Capital reiterated a hold rating on shares of AstraZeneca in a research report on Thursday, July 26th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of GBX 5,793 ($75.70).

Shares of AZN opened at GBX 5,822 ($76.07) on Tuesday. AstraZeneca has a 1 year low of GBX 4,260 ($55.66) and a 1 year high of GBX 5,520 ($72.13).

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

See Also: Float

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply